FIELD: chemical-pharmaceutical industry.
SUBSTANCE: invention relates to the chemical-pharmaceutical industry and is a pharmaceutical composition with an analgesic and an anti-inflammatory effect in the gel dosage form for topical administration, which contains 2.00–8.00 mass. % N-(2-adamantyl)-hexamethyleneimine hydrochloride (hymantane), 1.00–20.00 mass. % gelling polymer, 0.05–1.00 mass. % preservative, 1.00–10.00 mass. % suction amplifier and 61.00–95.95 mass. % solvent.
EFFECT: invention makes it possible to increase the effectiveness of the use of hymantane, to expand the arsenal of analgesic and anti-inflammatory agents of topical application, used in the treatment of diseases of the musculoskeletal system and relief of pain associated with injuries of various genesis, and also ensures rapid delivery of the drug substance to the local zone and reduces the frequency of side effects.
5 cl, 7 ex, 4 tbl
Title | Year | Author | Number |
---|---|---|---|
AGENT FOR MANAGING PAIN AND INFLAMMATION ACCOMPANYING NEURODEGENERATIVE DISORDERS | 2012 |
|
RU2559777C2 |
MEANS FOR OPIOID ABSTINENCE SYNDROME ARRESTING | 2017 |
|
RU2643588C1 |
WATER-SOLUBLE TYROSINE DERIVATIVES HAVING ANALGESIC, ANTI-INFLAMMATORY AND ANTIEDEMIC ACTION | 2017 |
|
RU2678563C1 |
PHARMACEUTICALLY ACCEPTABLE SALTS OF (S)-N-[4-(1-ADAMANTYL)BENZOYL]-α-AMINO ACIDS AND SYNTHESIS METHOD THEREOF | 2009 |
|
RU2417988C2 |
QUINAZOLIN-4(3H)-ONE DIMETHOXYBENZYLSULFO DERIVATIVE WITH ANALGESIC, ANTIPARKINSONIAN, ANXIOLYTIC, PSYCHOSTIMULATING ACTIVITY | 2021 |
|
RU2758333C1 |
TYROSINE HETEROCYCLIC AMIDES, HAVING ANALGESIC, ANTI-INFLAMMATORY AND ANTIEDEMIC ACTION | 2018 |
|
RU2685505C1 |
INJECTABLE DOSAGE FORM FOR TREATMENT OF PARKINSON'S DISEASE, METHOD FOR PREPARING AND USING IT | 2011 |
|
RU2520758C2 |
PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE | 2008 |
|
RU2423981C2 |
AGENT OF PEPTIDE STRUCTURE POSSESSING ANTI-INFLAMMATORY, ANTIBACTERIAL, WOUND-HEALING, REGENERATIVE, ANALGESIC, BURNTREATING ACTION AND BASED DOSAGE FORMS | 2012 |
|
RU2517213C2 |
SUPPOSITORIES FOR TREATMENT OF MODERATE AND HIGH-INTENSITY PAIN SYNDROME | 2019 |
|
RU2723960C1 |
Authors
Dates
2018-08-06—Published
2017-03-29—Filed